← Human Trials & Peer-Reviewed Studies
The interaction of growth hormone releasing hormone and somatostatin in the generation of a GH pulse in man
Plain-language guide to PMID 1684314 (1991): randomized controlled trial study of Somatostatin and GHRH (Growth Hormone-Releasing Hormone).
Key Facts
- PMID
- 1684314
- Journal
- Clinical endocrinology
- Year
- 1991
- Study type
- Randomized Controlled Trial
- Authors
- Hindmarsh PC et al. (5 authors)
- DOI
- 10.1111/j.1365-2265.1991.tb03548.x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Somatostatin and GHRH (Growth Hormone-Releasing Hormone) in this randomized controlled trial publication.
To study the regulation of the growth hormone (GH) response to growth hormone releasing hormone (GHRH) in the presence or absence of somatostatin pretreatment.
Who Took Part
PubMed indexes the participants as adults, men only.
Seven healthy adult male volunteers of normal height and weight and aged between 19 and 29 years underwent four separate studies (each containing three cycles in one day) in random order.
In all studies, samples were collected for the measurement of serum GH concentration at 15-minute intervals from time 0 to 180 minutes and then at 5-minute intervals for a further 60 minutes, this cycle being repeated three times.
How the Study Was Run
The researchers set it up as a randomized study.
Random assignment meant chance, not the researchers, decided who got Somatostatin and who got the comparison, which limits bias.
The studies were separated from each other by at least a week.
On day 1, three consecutive cycles (between 0800 and 2000 hours) consisted each of a saline infusion for 3 hours which was stopped prior to a bolus injection of saline and followed by 60 minutes of more intensive blood sampling.
On day 2, the bolus injections were of GHRH given after saline infusion.
On days 3 and 4 somatostatin infusions were administered instead of saline over the 3-hour periods followed by bolus injections of saline or GHRH respectively.
Serum GH concentrations were analysed by serial array averaging.
What Was Measured
PubMed files the paper under topics including Blood Glucose, Drug Interactions, Growth Hormone, Growth Hormone-Releasing Hormone, Insulin, Periodicity and Somatostatin.
What This Means in Plain Language
The paper is a randomized study of Somatostatin and GHRH (Growth Hormone-Releasing Hormone).
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 1991 (Clinical endocrinology), a journal based in England.
More context: the Somatostatin compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.
Our Notes on the Compounds
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.